Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.56 |
| ▸ | F3 | P13726 | 1/20 | 0.56 |
| ▸ | PYGL | P06737 | 5/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24019647 | 0.83 | F7 (0.66) | F7F3PYGLALOX15HRH4 | |
| SCHEMBL9040655 | 0.81 | ALOX15 (0.80) | PYGLALOX15HRH4HRH3 | |
| SCHEMBL4454538 | 0.80 | DRD2 (0.62) | HRH4IDO1FLT3 | |
| SCHEMBL22529428 | 0.78 | FLT3 (0.52) | PYGLHRH4KMT2AMEN1NPC1 | |
| SCHEMBL24196566 | 0.78 | KDM4E (0.59) | HRH4IDO1FLT3 | |
| SCHEMBL11888230 | 0.77 | PYGL (0.55) | PYGLALOX15HRH4HRH3 | |
| SCHEMBL18357507 | 0.76 | FLT3 (0.60) | F7F3PYGLHRH4KMT2A | |
| SCHEMBL2729831 | 0.75 | F7 (0.72) | F7F3PYGLHRH4KMT2A | |
| SCHEMBL23112798 | 0.74 | HSD17B3 (0.55) | NPC1RAB9A | |
| SCHEMBL29766264 | 0.74 | HSD17B3 (0.55) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
| US-7598398-B2 | Acyl indoles, compositions containing such compounds and methods of use | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20070088071-A1 | Acyl indoles, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | F7 2480/4885F3 2398/4885PYGL 1009/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | F7 2480/4885F3 2398/4885PYGL 1009/4885 |
| US-20070088071-A1 | Acyl indoles, compositions containing such compounds and methods of use | GPR119, IAPP, GLP1R | F7 4483/4885F3 3303/4885PYGL 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.